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Abstract
This manuscript describes the basics of proteomic and metabolic profiling of blood serum and plasma from patients with 
psychiatric disorders. It will also explain the rationale behind the use of these bodily fluids, due to the need for user-friendly 
and rapid tests in clinics with simple sampling procedures. It has become evident over the last 15 years or so that psychiatric 
disorders are whole-body diseases and the bloodstream is a means of molecular transport that therefore provides a conduit 
for two-way communication with the brain. Here we also describe some of the basic biomarker findings from studies of 
serum or plasma from patients with psychiatric disorders like schizophrenia, major depression, and bipolar disorder. Finally, 
we will discuss potential future advancements in this area, which include the development of hand-held devices containing 
miniature proteomic and metabolic assays which can be used for facilitating diagnoses in a point-of-care setting and yield 
results in less than 15 minutes from a single drop of blood.
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Introduction
The use of blood serum and plasma has increased over more 
than a decade in molecular profiling studies of psychiatric 
disorders. The rationale stems from the fact that, although 
psychiatric disorders appear to be generated in the brain, the 
effects of these diseases can be seen throughout the whole 
body. Long-standing scientific and medical research has shown 
that the brain is integrated in virtually all physiological func-
tions of the body, and this is reflected in the composition of 
blood proteins and other bioactive molecules. One of the best 
examples is the well-known fight-or-flight reflex (Laborit, 1976). 
This begins with a perception of danger, mediated by a region 
of the brain called the amygdala, which stimulates the release 
of a hormone called corticotrophin releasing factor (CRF) from 
the hypothalamus, which, in turn, causes increased secretion 
of adrenocorticotrophic hormone (ACTH) from the pituitary into 
the blood. Next, the ACTH circulates throughout the blood and 
acts on the adrenal glands to release the steroid hormone cor-
tisol. The increased circulating cortisol levels cause an increase 
in blood pressure as well as a rise in blood glucose concentra-
tions to serve as the fuel for the muscular reactions required in 
the response. The final stage completes the loop as the elevated 
cortisol levels exert a negative feedback effect on the hypotha-
lamic-pituitary-adrenal (HPA) axis through down-regulation of 
glucocorticoid receptors in the brain and pituitary.
But it is not just the effects on the HPA axis which can give an 
indication of brain function. There are countless physiological 
circuits of the body that can be monitored by changes in blood 
molecules, including the response to food intake (Mastorakos 
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and Zapanti, 2004), pregnancy (Smith and Thomson, 1991), the 
inflammation response (Späth-Schwalbe et  al., 1994; Straub 
et  al., 2011), and the presence of metabolic disorders such as 
insulin resistance and diabetes (Pasquali et  al., 2006; Reagan, 
2007). In fact, impaired functioning of many hormonal systems 
of the body, such as the insulin signalling cascade, can contrib-
ute to impaired brain functions, including memory and cogni-
tive deficits (Solas et  al., 2010). In support of the whole-body 
concept of psychiatry, recent investigations have shown that 
molecular signatures for schizophrenia, major depressive dis-
order, and bipolar disorder can be detected in the circulating 
blood. Most of these molecules converge on the metabolic and 
inflammatory pathways, although changes in other molecules 
representing antioxidant and growth factor pathways have also 
been found. This is highly useful since blood can be taken from 
living patients in a minimally invasive way during progressive 
stages of the disease or following treatment, whereas other tis-
sues, such as those in the brain, are only available for analysis 
at autopsy.
Clinical Need
There is currently a need for molecular biomarkers in stud-
ies of major psychiatric disorders, since these are expected 
to help improve diagnosis and treatment outcomes. However, 
research in this field has thus far not lived up to its potential. 
This is most likely due to the fact that psychiatric diseases are 
still classified using diagnostic concepts which could be sub-
jective. Furthermore, these disorders are heterogeneous and 
sometimes overlap in their aetiology and symptoms. The avail-
ability of accurate biomarker tests for specific psychiatric dis-
orders could be used to classify at-risk individuals, as well as 
those with the full-blown illness. Furthermore, the availability 
of tests that can be used to monitor treatment or even predict 
treatment response would help to improve patient outcomes. It 
is important to state that this molecular approach should not be 
used as a replacement for the current clinical methods, but as 
an add-on feature. The old ways do work, just not as effectively 
as expected.
The above movement towards incorporation of molecu-
lar tests is in line with the National Institute of Mental Health 
Research Domain Criteria (RDoC) project, which aims to develop 
a classification system for mental health disorders that can be 
linked to the underlying dysfunctional pathways (Cuthbert and 
Insel, 2013). This is important, since improved understanding 
of these pathways will lead to more targeted treatments. With 
this in mind, the RDoC project aims to: (1) integrate multiple 
scientific disciplines to identify basic behavioral components of 
psychiatric disorders that can be associated with neurobiologi-
cal dysfunction; (2) identify features of these components which 
can be used to define the normal and pathological states; and 
(3) establish and combine standardized and validated methods 
to produce molecular, environmental, behavioral, and neurobio-
logical profiles of these disorders for improved classification.
Why Choose Proteomics and Metabolomics 
To Study Psychiatric Disorders?
Biomarkers are physical characteristics that can be measured and 
used as an indication of physiological factors such as good health, 
disease, toxicity or drug response (Biomarkers Definitions Working 
Group et al., 2001). For practical purposes, it is important that a 
biomarker can be measured with high accuracy and reproducibil-
ity, within a short time frame, and at an affordable cost. Ideally, a 
biomarker should also reflect in some way the underlying nature 
of the disorder or condition being measured. In psychiatry, various 
types of biomarker measurements have emerged, including those 
derived from brain imaging analyses, psychiatric tests, and elec-
trophysiological responses. This review will focus on proteomic 
and metabolomic profiles, or “fingerprints,” in blood samples. In 
other words, we will be describing techniques that use chang-
ing patterns of blood molecules as a means of diagnosis. Since 
changes in physiological states are dynamic in nature, they are 
likely to introduce alterations in numerous proteins and metab-
olites that converge on similar pathways. Therefore, it would be 
most useful to apply proteomic and metabolomic methods, as 
they can target tens to hundreds of molecules simultaneously, 
which should result in a more complete fingerprint and therefore 
a better understanding of the affected pathways. This is like the 
difference between fishing using specific bait for only one type of 
fish compared with trawling using a wide net, which can lead to 
the capture of many different types of fish.
Proteomic and Metabolomic Technologies
Most researchers now consider the study of proteins (prot-
eomics) and metabolites (metabolomics) in a large-scale man-
ner to be among the most informative reflections of biological 
functions, considering that these molecules actually carry out 
or respond to most processes of the body. Furthermore, the 
majority of drugs in use today are designed to turn on or turn 
off proteins, such as receptors or enzymes, or induce metabolic 
changes, which can be seen as turnover of various proteins 
and small molecules. The term “proteome” was coined by Marc 
Wilkins in 1994 while he was a PhD student working on the con-
cept of the expressed proteins of a genome (Wilkins et al., 1996). 
But what does proteome actually mean? The proteome is the set 
of expressed proteins by a cell, tissue, or organism, in a given 
moment, under a given condition. As a reminder, each cell in an 
organism contains the same genomes, but only some of these 
are expressed as proteins, depending on, for example, the type 
of cell, the time of day, the presence of disease, or responses to 
drugs or toxins. The word “metabolome” was first used in a 1998 
publication by Tweeddale, Notley-McRobb, and Ferenci as the 
total metabolite pool in a cell, tissue, or organism (Tweeddale 
et al., 1998). Proteomics and metabolomics are, respectively, the 
methods that study the proteome and the metabolome.
The rationale for looking at the blood is that most biomarker 
studies of psychiatric disorders are stymied by the difficulties 
and the sheer inappropriateness of accessing and studying brain 
samples from living patients. However, the identification of cor-
relating biomarkers in the periphery is the approach being taken 
by most researchers today, since these can reflect brain function 
and because blood-based tests are more amenable to clinical 
studies. Several psychiatric disorder studies aiming to identify 
molecular biomarker candidates have now been carried out 
using multi-protein arrays, mass spectrometry, or nuclear mag-
netic resonance (NMR) profiling platforms. These techniques 
enable the simultaneous detection of hundreds of proteins or 
small molecules, some of which can be altered in the disease 
state and therefore used as potential biomarker fingerprints.
Proteomic Techniques
Multiplex Immunoassay
Blood serum and plasma contain many important bioactive 
or regulatory molecules, such as hormones, growth factors, 
and cytokines. However, most of these are present only at low 
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concentrations and therefore require detection by high-sen-
sitivity platforms. One of the best methods to achieve this is 
multiplex immunoassay (Fulton et  al., 1997; Figure  1). These 
assays are constructed and carried out using serum or plasma 
samples as follows: (1) micro-beads are loaded with different 
ratios of red and infrared dyes to give unique fluorescent sig-
natures; (2) a capture antibody is attached to the fluorescent 
bead surface such that each specific antibody is attached to a 
bead with a specific signature; (3) the sample is added and a tar-
get molecule (in this case, Figure 1 shows insulin as the target) 
binds to antibody-bead conjugate; (4) a fluorescently-labelled 
detection antibody is added which binds to the target molecule 
in a sandwich format; and (5) the beads are streamed though a 
reader and analyzed by two lasers for identification and quan-
tification of the analyte present. For the last step, the lasers can 
identify which analytes are present by measuring the unique 
fluorescent signature of each bead and can determine the 
quantity of analytes present by measuring the amount of the 
fluorescent tag associated with each bead (proportional to the 
analyte concentration). In the example shown, it would be pos-
sible to determine the concentrations of insulin, brain-derived 
neurotrophic factor, and interleukin 1 simultaneously, as each 
antibody-bead conjugate would have a distinct signature. Thus 
far this method has been used in many disease areas, includ-
ing the study of multiple psychiatric disorders, such as schizo-
phrenia, major depressive disorder, and bipolar disorder (Chan 
et al., 2014).
Two-Dimensional Gel Electrophoresis
Patrick O’Farrell first presented the two-dimensional gel elec-
trophoresis (2DE) method in 1975, and this technique single-
handedly revolutionized the discovery of biomarkers (O’Farrell, 
1975). Just before completion of the human genome project in 
2001, 2DE remained the method of choice for comparative pro-
teome analyses. The method works as follows: (1) proteins in 
the samples are applied to a strip gel and separated according to 
their isoelectric point (the point at which no net charge on the 
protein occurs) using isoelectrofocusing; (2) they are separated 
according to their apparent molecular weight by application of 
the strip onto a sodium dodecylsulphate polyacrylamide gel and 
electrophoresed again; and (3) the protein spots in the gels can 
be visualized with any number of stains (such as Coomassie 
Blue or Sypro Ruby) and then quantitated using an imaging 
software (Figure 2). The resulting effect can be visually striking 
and often resembles a constellation or a small galaxy of stars.
2DE techniques allow the study of intact proteins, but there 
are some problems with analyses of blood serum or plasma 
samples. This occurs mainly due to the fact that blood contains 
a massive concentration range of proteins spanning more than 
10 orders of magnitude (Anderson and Anderson, 2002). This 
means that very abundant proteins such as albumin would 
appear as large blobs on the gels and eclipse less abundant 
proteins such as the cytokines. For this reason, other methods 
began to be used increasingly for proteome analysis.
Mass Spectrometry
Just before the end of the human genome project, the shotgun 
mass spectrometry revolution began as a more sensitive and 
higher throughput approach for proteomic biomarker identifi-
cation (Link et al 1999). These methods are called “shotgun” as 
the protein mixtures can be cleaved with enzymes to generate 
smaller protein fragments called peptides (resembling shotgun 
pellets), which are the actual analytes in this approach. This is 
done since most intact proteins are too large and complex in 
their structure to be analyzed directly in a mass spectrometer. 
In the next phase, the peptides are separated according to their 
physiochemical properties by liquid chromatography so that 
they do not enter the mass spectrometer at the same time. As 
the peptides leave the column and enter the mass spectrometer 
on-line, they are ionized by electrospray, which is basically the 
application of an electric charge to evaporate all the fluids, leav-
ing the peptides in a changed plasma state. This allows the pep-
tide ions to be accelerated by magnets in the mass spectrometer 
and the peptides speed towards a detector, essentially according 
to their precise mass (heavy peptide ions move slower than light 
ones). Quantitation can be achieved since the amount of a given 
peptide hitting the detector per unit of time is proportional to 
the quantity of that peptide and, therefore, the corresponding 
parent protein (Figure 3). Simultaneously, the sequence of the 
peptide can be determined by streaming in a gas like nitro-
gen, which bombards the peptides, causing them to break 
into smaller pieces (not shown in the figure). Determining the 
masses of these pieces can then allow researchers to derive the 
amino acid sequences that make up the peptides, which could 
then be used to search a protein database to obtain the identi-
fication of the parent protein. This method is also compatible 
Figure 1. Multiplex immunoassay. Samples are added to dye-coded microsphere-antibody conjugates that target specific proteins. After incubation with a second 
antibody containing a fluorescent label, the mixtures are streamed through a reader, which uses lasers for identification of the antibody-microsphere conjugates and 
quantitation of the bound analytes.
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with metabolomic analysis. In this case, there is no need for 
enzymatic cleavage of the molecules, as these are already of a 
manageable size. In this approach, the sample can be infused 
directly into the mass spectrometer, the quantity determined 
as above, and the identity deciphered through molecular weight 
comparisons with known standards.
Metabolomic Techniques
1H-NMR Spectroscopy
Although mass spectrometry can also be employed, 1H-NMR 
is chiefly used for metabolomic and small molecule analyses 
and does not require separation or pre-fractionation of the 
molecules in some cases. A key advantage of this approach is 
Figure 2. Two-dimensional gel electrophoresis. Proteins are extracted from a tissue or other sample and then separated by electrophoresis in two dimensions. The 
first dimension is isoelectric focusing, during which proteins are separated according to their isoelectric points (the state of zero net charge). The second dimension is 
detergent-based gel electrophoresis, during which the proteins are separated according to apparent molecular weight. The resulting protein spots can be subjected to 
image analysis and quantitated.
Figure 3. Main stages of mass spectrometry profiling. This method can screen hundreds to thousands of proteins or small molecules in one run, depending on whether 
or not a pre-fractionation step is applied. In the case of proteomics, the method requires enzymatic digestion of the proteins to produce smaller manageable peptides. 
This step is omitted in metabolomics approaches since the analytes in question are already of a manageable size.
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the analytical reproducibility and sheer simplicity of the sam-
ple preparation step. However, this method is less sensitive 
compared to mass spectrometry–based approaches (Griffin, 
2003; Beckonert et al., 2007). The technique gives information 
about the structural properties of molecules and is therefore 
suited for identification purposes. 1H (proton) NMR works by 
tracking the behavior of protons when they are introduced 
into a very strong magnetic field. In this scenario, the nuclei 
of the protons on molecules line up with the magnetic field, 
similar to the way that a compass needle aligns with the mag-
netic field of the Earth. However, the NMR magnetic field is 
around four orders of magnitude stronger than that envelop-
ing the Earth. The NMR procedure begins with the application 
of radio-frequency pulses to the sample. This stimulates the 
nuclei to rotate away from their equilibrium position so that 
they can rotate around the axis of the magnetic field. The fre-
quency of the rotation is related to the chemical and physi-
cal environment of the atom within the molecule. This means 
that by using different combinations of radio pulses it is pos-
sible to determine how each atom interacts with other atoms 
in the same molecule, yielding the structure and therefore the 
identity of the molecule (Figure 4). NMR can also be used to 
monitor relative changes in the levels of key analytes such as 
amino acids, neurotransmitters, and neurotransmitter precur-
sors or metabolites, making it useful for biomarker studies of 
psychiatric disorders.
Molecular Fingerprints in Psychiatric 
Disorders
More than 100 studies have now been performed that have 
looked at proteomic and metabolomic biomarker changes in 
the serum or plasma of patients with psychiatric disorders 
(Sethi and Brietzke, 2015; Chan et  al., 2014; Nascimento and 
Martins-de-Souza, 2015). It should be noted that the most 
informative and useful biomarker test suggested by clinicians 
would be one that could distinguish one psychiatric disorder 
from another. This would appear to be difficult at first glance 
since virtually all of these disorders display changes in cir-
culating proteins and small molecules involved in similar 
molecular pathways, such as hormone signalling (adiponec-
tin, adrenocorticotrophic hormone, cortisol, insulin, leptin, 
prolactin, testosterone), energy metabolism (cholesterol, 
glucose, lactate), growth factor (brain-derived neurotrophic 
factor, epidermal growth factor, nerve growth factor), inflam-
mation (cytokines, antibodies, acute phase response proteins), 
and oxidative/reduction pathways (glutathione, malondialde-
hyde, methylglyoxal, dehydroepiandrosterone; Lo et al., 2009; 
Bicikova et al., 2011; Yang et al., 2013; Chan et al., 2014; Huang 
et  al., 2014; Huang and Lin, 2015; Table  1). Although some of 
these biomarkers have been reported to be altered in one or 
two of these disorders (suggesting that these may be unique 
for that particular disorder), the main problem lies in the fact 
that these have not been compared across the disorders in the 
same study. Of course, this would require a massive integration 
of efforts across multiple clinical locatoins to acquire a suffi-
cient number of samples to add enough statistical power to the 
investigation. Most importantly, it will also require adoption of 
the same standard operating procedures for all of these loca-
tions regarding stages of the procedure such as patient recruit-
ment and assessment, sample collection and storage, as well 
as standardization of the proteomic and metabolic platforms 
and data analysis methods used.
Molecular Tests to Improve Treatment 
Response
Previous studies have shown that basic measurements of physi-
cal characteristics, like waist circumference and body mass 
index, or testing the levels of fat-based molecules, such as tri-
glycerides and high density lipoproteins, can be used with some 
accuracy to predict whether or not a patient with schizophrenia 
will develop metabolic side effects in response to antipsychotic 
treatment (Jin et al., 2010). Therefore, a test which incorporates 
measurements such as these would be useful for identifying 
those patients who would be most likely to benefit from add-
on treatments with antidiabetic drugs, as these would help to 
minimize the metabolic side effects such as insulin resistance 
or weight gain. A proteomic study showed that schizophrenia 
patients with higher serum levels of the pituitary hormone pro-
lactin have a better outcome after long-term treatment with 
antipsychotics (Shrivastava et  al., 2012). Another molecular 
profiling study found that the circulating levels of prolactin, the 
metabolism-related fatty acid binding protein, and the inflam-
mation pathway molecules ferritin, C-reactive protein, myoglo-
bin, complement factor H, and interleukin-16 could be used to 
predict improvement in positive symptoms of schizophrenia 
(psychosis, delusions, hallucinations) following antipsychotic 
treatment (Schwarz et  al., 2012). The same study also found 
that measurement of the levels of insulin and the inflammation 
marker matrix metalloproteinase 2 were useful for prediction 
of improvements in negative symptoms (depression, flattened 
Figure 4. Principles of the proton nuclear magnetic resonance method for determining molecular structure.
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effect, listlessness). The same study also found that if a patient 
had low levels of the hormones insulin and leptin in combina-
tion with high levels of the inflammatory protein transform-
ing growth factor–beta, they were more likely to have a relapse 
more rapidly than those patients who did not have this same 
molecular pattern. Finally, a recent study showed that pre-
treatment levels of molecules involved in fatty acid metabolism 
could be used to predict response to treatment with the antip-
sychotic olanzapine (Tomasik et al., 2015). It should be stressed 
that although these studies show considerable promise, further 
investigations are required to confirm the findings and then 
translate measurement of these analytes into a user-friendly 
format for testing in a clinical setting.
Future Prospects
In the near future, it is conceivable that the increasing use of 
circulating proteomic and metabolomic biomarkers will lead to 
more extensive biological signatures in people that reflect the 
physiological changes occurring in health and disease. It is clear 
from the literature that some blood-based biomarker candidates 
have now been replicated across several studies of psychiatric 
disorders and converge mostly on the pathways of hormonal 
metabolism and inflammation. Also, recent studies have begun 
to emerge that identify biomarker candidates to predict psy-
chiatric disease development in at-risk individuals. Some of 
these tests have shown sensitivities of approximately 90%. This 
includes tests for schizophrenia (Chan et al., 2014; Perkins et al., 
2014; Table 2), major depressive disorder (Gottschalk et al., 2015; 
Table 3), and bipolar disorder (Haenisch et al., 2015; Table 4). The 
exciting point of all of these studies is that they demonstrate the 
presence of a disease signature in at-risk individuals months 
to years before full clinical manifestation. However, one draw-
back of all of these investigations is that each was carried out 
using retrospective sample collections. It will be important to 
validate the findings using new sample collections in prospec-
tive investigations.
Another point to consider is that all of the existing proto-
type tests for diagnosis, disease prediction, and drug treatment 
response monitoring have been devised using current prot-
eomic and metabolomic platforms. These are typically com-
prised of multiple large components that require considerable 
technical expertise and knowledge for correct operation, and 
most do not return results rapidly enough to be of use in point-
of-care scenarios. In line with this, a market has emerged for 
the development of novel and more effective diagnostic and 
treatment approaches. Multiplex biomarker tests have now 
been developed that use the multiplex immunoassay system on 
diagnostic devices, which are approximately the size of a credit 
card. These feature a high degree of modularity, allowing vari-
ous assay types and formats. These tests have many advantages 
over existing approaches, including that they are user friendly, 
require no expertise, are rapid, and have a low cost. Such a test 
has been developed by the scientists at the Fraunhofer Institute 
in Germany and normally involves application of blood drops 
into a small chamber in a card, which is inserted into a book-
sized reader to produce the diagnosis “score” in less than 15 
minutes (Schumacher et  al., 2012; Figure  5). The idea is that 
these devices, which feature analyses of both proteomic and 
small molecule biomarkers, could be used directly in a doctor’s 
office, with the result returned within the timeframe of the visi-
tation period. Thus, a major benefit will be the rapid turnover, 
Table 1. Pathways and Associated Molecule or Molecular Class Found to be Altered in Psychiatric Disorders
Pathway Molecule Platform
Hormone signalling Adiponectin MIA
Adrenocorticotropic hormone MIA
Cortisol MIA
Insulin MIA
Leptin MIA
Prolactin MIA
Testosterone MIA, LC-MS/MS
Energy metabolism Cholesterol MIA, LC-MS/MS
Glucose NMR
Lactate NMR
Apolipoprotein AI MIA, 2DGE
Apolipoprotein AIV MIA, 2DGE
Growth factor Brain-derived neurotrophic factor MIA
Epidermal growth factor MIA
Nerve growth factor MIA
Inflammation Cytokines MIA
Antibodies MIA, 2DGE, LC-MS/MS
Acute phase response proteins MIA, 2DGE, LC-MS/MS
Transferrin 2DGE
Fibrinogen 2DGE
Oxidative/reduction Glutathione NMR
Methylglyoxal NMR
Dehydroepiandrosterone NMR
Glutathione peroxidase MIA, 2DGE, LC-MS/MS
Superoxide dismutase MIA, 2DGE, LC-MS/MS
Protein synthesis Protein disulfide isomerase 2DGE
T-complex protein subunit beta 2DGE
Molecular class was used for the inflammation-related molecules given the high number of molecules affected in this class. 2DGE, two-dimensional gel electropho-
resis; LC-MS/MS, liquid chromatography tandem mass spectrometry; MIA, multiplex immunoassay; NMR = 1H-nuclear magnetic resonance spectroscopy.
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Table 2. Identification of Serum Biomarkers for Prediction of Schizophrenia Before Disease Onset
Molecular pathway Analyte Publication
Inflammation Alpha-2 macroglobulin Chan et al., 2015
Beta-2 microglobulin Chan et al., 2015
Carcinoembryonic antigen Chan et al., 2015
Chemokine (C-C) motif ligand 8 Perkins et al., 2014
Haptoglobin Chan et al., 2015
Immunoglobulin-A Chan et al., 2015
Immunoglobulin-E Perkins et al., 2014
Interleukin-1 receptor antagonist Chan et al., 2015
Interleukin-beta Perkins et al., 2014
Interleukin-10 Chan et al., 2015
Interleukin-7 Perkins et al., 2014
Interleukin-8 Perkins et al., 2014; Chan et al., 2015
Interleukin-13 Chan et al., 2015
Macrophage migration inhibitory factor Chan et al., 2015
Matrix metalloproteinase 7 Perkins et al., 2014
Receptor for advanced glycosylation end products Chan et al., 2015
Serum glutamic oxaloacetic transaminase Chan et al., 2015
Tenascin C Chan et al., 2015
Uromodulin Perkins et al., 2014
Von Willebrand factor Chan et al., 2015
Hormone signalling Cortisol Perkins et al., 2014
Follicle-stimulating hormone Chan et al., 2015
Growth hormone Perkins et al., 2014
Leptin Chan et al., 2015
Pancreatic polypeptide Chan et al., 2015
Resistin Chan et al., 2015
Testosterone (total) Chan et al., 2015
Thyroid stimulating hormone Perkins et al., 2014; Chan et al., 2015
Growth factor signalling AXL receptor tyrosine kinase Chan et al., 2015
Insulin-like growth factor-binding protein 2 Chan et al., 2015
Stem Cell Factor Perkins et al. 2014; Chan et al., 2015
Clotting cascade Angiotensin-converting enzyme Chan et al., 2015
Factor VII Perkins et al., 2014; Chan et al., 2015
Lipid transport Apolipoprotein-D Perkins et al., 2014
Malonaldehyde-modified low density lipoprotein Perkins et al., 2014
The table shows the molecular pathways and specific molecules covered by these tests as well as the associated publications.
Table 3. Identification of Serum Biomarkers for Prediction of Major Depression Before Disease Onset. The table shows the molecular pathways 
and specific molecules covered by these tests as well as the associated publications
Molecular pathway Analyte Publication
Inflammation Carcinoembryonic antigen Haenisch et al., 2015
CD5 Haenisch et al., 2015
CD40 Haenisch et al., 2015
Cystatin C Haenisch et al., 2015
ENRAGE Haenisch et al., 2015
Growth-regulated alpha protein Haenisch et al., 2015
Interleukin-1 receptor antagonist Haenisch et al., 2015
Interleukin-10 Haenisch et al., 2015
Macrophage inflammatory protein-1 beta Haenisch et al., 2015
Matrix metalloproteinase-3 Haenisch et al., 2015
Matrix metalloproteinase-7 Haenisch et al., 2015
Matrix metalloproteinase-9, total Haenisch et al., 2015
Receptor for advanced glycosylation end products Haenisch et al., 2015
Serum amyloid P-component Haenisch et al., 2015
Tumor necrosis factor receptor-Like 2
Growth factor signalling Hepatocyte growth factor Haenisch et al., 2015
Lipid transport Apolipoprotein A1 Haenisch et al., 2015
Apolipoprotein A2 Haenisch et al., 2015
Lipoprotein (a) Haenisch et al., 2015
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which will help to cut down on waiting times for lab test results, 
which often take days to weeks using the larger platforms. 
Furthermore, these devices could contain a USB port for connec-
tion to computers and other devices for transmission of data. 
This opens up a new realm of possibilities.
Point-of-care-type tests that are already in use include 
those used to measure blood gases and ions, as well as bio-
markers of cardiac problems, diabetes, pregnancy, specific 
infectious diseases, or the presence of alcohol or drugs of 
abuse. These devices usually consist of a test strip, lateral 
flow, slides, flow-through tubes, and cassettes, and they often 
have built-in meters and displays for easy visualization of 
the test results. Another requirement of point-of-care devices 
which can measure proteomic and metabolomic biomarkers 
is mobile communication and internet access so the data can 
be organized, analysed, and formatted for simple and manage-
able presentation to the end users. This would allow testing 
using real-time multiplexed sensors of proteomic and metab-
olomic biomarkers, combined with artificial intelligence and 
mobile communication systems for the analysis and display 
of the results.
A movement towards mobile phone applications is also 
underway in molecular diagnostics. Mobile phones have 
now become virtually ubiquitous, with a number somewhere 
around the 6 billion mark for actual subscriptions (most of the 
world’s population; http://mobithinking.com/mobile-market-
ing-tools/latest-mobile-stats/a#subscribers). The smartphone 
combines normal voice and text messaging services with 
information technology, supporting applications, and sensors, 
as well as internet access and connectivity with other devices, 
allowing for new medical applications (Klasnja and Pratt, 
2012). In fact, smartphone-based interventions have already 
shown initial promise in improving individual outcomes in a 
variety of health conditions, diseases, and habit control, and 
thus have high potential in the future treatment and man-
agement of psychiatric disorders. For example, they could be 
used to improve the attendance of patients at their medical 
appointments, provide more rapid diagnosis and treatment, 
and improve communication, along with having a positive 
impact on behaviors such as smoking cessation and increased 
medication compliance, as well as clinical enhancements such 
as lowering of stress levels. Most of these involve automated 
text or voicemail reminders of encouragement on preventative 
behaviors or self-management.
Potentially the most exciting recent developments have 
included the construction of multiplex immunoassay tests 
on a hand-held colorimetric micro-plate reader, which uses 
3D-printed opto-mechanics for illumination of miniature reac-
tion wells on a light-emitting diode optical fibre array (Berg 
et  al., 2015). In this approach, the resulting images can even 
be transmitted to central servers for diagnostic results output 
within 1 minute. Thus far, this mobile platform has been tested 
in a clinical microbiology laboratory using mumps, measles, and 
herpes simplex I and II virus immunoglobulin tests, and these 
had accuracies greater than 98%. We should expect that simi-
lar tests for other diseases such as psychiatric disorders will be 
available in the near future based on analysis of validated prot-
eomic and metabolomic biomarkers. However, this is still some 
distance in the future, as many stages such as validation test-
ing are required to ensure that only the most robust biomarker 
candidates are incorporated into these formats. In this way, 
the diagnosis and treatment of psychiatric disorders can move 
forward into the 21st century in pace with that of other medi-
cal areas such as cardiovascular disease, diabetes, and cancer. 
Most importantly, this will lead to more personalized medicine 
approaches (Evers, 2009), which will enable treatment of the 
right patients with the right drug at the right time for better 
outcomes.
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Figure 5. Credit card-sized diagnostic tests of proteomic/metabolomic biomarkers for diseases which can be achieved in less than 15 minutes using a single drop of 
blood. This approach has been pioneered by the scientists from the Fraunhofer Institute.
Table 4. Identification of Serum Biomarkers for Prediction of Bipolar Disorder Before Disease Onset
Molecular pathway Analte Publication
Inflammation Collagen IV Gottschalk et al., 2015
Vascular cell adhesion molecule 1 Gottschalk et al., 2015
Vitronectin Gottschalk et al., 2015
Growth factor signalling Insulin-like growth factor binding protein 3 Gottschalk et al., 2015
Receptor tyrosine kinase AXL Gottschalk et al., 2015
The table shows the molecular pathways and specific molecules covered by these tests as well as the associated publications.
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